Daptomycin: a comparison of two intravenous formulations.

scientific article published on 29 June 2018

Daptomycin: a comparison of two intravenous formulations. is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.2147/DDDT.S167010
P932PMC publication ID6030942
P698PubMed publication ID29988771

P2093author name stringLuke Mendez-Vigo
Sachin Mittal
Kenneth C Lamp
Celeste Frankenfeld
Kaitlin N Keller
Shellie R Bertolami
Yanira Melendez
P2860cites workPhysical and chemical compatibility of daptomycin with nine medicationsQ45029806
Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patientsQ68937442
Intravenous immunoglobulin-induced osmotic nephrosisQ72159416
Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infectionsQ26752922
The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infectionsQ34330270
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureusQ34558111
Daptomycin: a review 4 years after first approvalQ36972980
Sucrose or honey at breakfast have no additional acute hyperglycaemic effect over an isoglucidic amount of bread in type 2 diabetic patientsQ38591526
P275copyright licenseCreative Commons Attribution-NonCommercialQ6936496
P407language of work or nameEnglishQ1860
P921main subjectlipidQ11367
antibioticQ12187
peptideQ172847
polycyclic compoundQ426145
P304page(s)1953-1958
P577publication date2018-06-29
P1433published inDrug Design, Development and TherapyQ2566724
P1476titleDaptomycin: a comparison of two intravenous formulations
P478volume12

Reverse relations

Q57492422as a Prominent Resource of Future Anti-MRSA Drugscites workP2860

Search more.